Cerus Endovascular receives CE approval for Neqstent

GlobalData Healthcare 11 May 2020 (Last Updated May 11th, 2020 16:26)

Cerus Endovascular receives CE approval for Neqstent

Cerus Endovascular has secured Conformité Européenne (CE) mark approval for its coil-assisted flow diverter Neqstent. However, GlobalData expects that the device may experience a slow uptake due to the Covid-19 pandemic.

In April, Cerus Endovascular received CE approval for Neqstent. The coil-assisted flow diverter is designed as a disc and is deployed inside an aneurysm, specifically across the neck, similar to Cerus’ Contour device. By deploying the device within the aneurysm, the physician is only required to measure the neck of the aneurysm. This eliminates the need to conform to the dimensions of the parent vessel, which is considered a drawback of traditional coil-assisted stents. The device is primarily designed as an intrasaccular flow-diverting device to be used in combination with coils.

Cerus Endovascular entered the aneurysm market in February, receiving CE approval for its Contour Neurovascular System. By receiving CE approval for Neqstent, Cerus’ portfolio has expanded into the coil-assisted stent market. Neqstent’s hybrid design will also allow it to compete within the intrasaccular flow disruptor and flow diverter markets, two of the fastest-growing spaces in the aneurysm treatment devices market. GlobalData expects the coil-assisted stent market to grow at a Compound Annual Growth Rate (CAGR) of approximately 3.8% in the next ten years.

Due to the ongoing Covid-19 pandemic, non-essential and elective surgical procedures have been postponed to prioritise and divert resources to the care for Covid-19 patients. While ruptured aneurysms will continue to be treated due to their urgent and essential nature, the re-introduction of the treatment of unruptured aneurysms may take some time to recover as hospitals slowly direct resources back to these procedures. GlobalData expects that the endovascular treatment for aneurysms has reduced by at least 40% as a result of the suspension of elective procedures.

Cerus Endovascular plans on a slow commercial market release across Europe toward the end of this year. While many of the European countries that have been impacted heavily by Covid-19 are set to reach their peak in April and May, GlobalData expects that the uptake of Cerus Endovascular’s Neqstent and Contour devices will experience a slow uptake. In addition to the general slow re-introduction of non-essential procedures, Cerus will have to compete against major competitors that have larger portfolios and distribution networks, resulting in a faster recovery in the market.